Severe acute respiratory syndrome-related coronavirus is inhibited by interferon- alpha.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 15031783.
- Also identified by PMC identifier 7109643.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Current treatment schemes for severe acute respiratory syndrome (SARS) include broad-spectrum antibiotics, glucocorticoids, and ribavirin. We evaluated the susceptibility of the SARS-related coronavirus (SARS CoV) to ribavirin and interferon (IFN)- alpha in vitro by use of cytopathic effect, plaque assay, and immunoblot analysis. Ribavirin did not inhibit viral growth at concentrations attainable in human serum. In contrast, IFN- alpha showed an in vitro inhibitory effect starting at concentrations of 1000 IU/mL. In conclusion, ribavirin alone is unlikely to be beneficial in the prophylaxis or treatment of SARS CoV infections. Clinical trials with IFN- alpha might be justified to determine a beneficial effect on the outcome of SARS.
Medical subject headings
- Antiviral Agents
- Interferon-alpha
- Severe acute respiratory syndrome-related coronavirus
- Severe Acute Respiratory Syndrome